<DOC>
	<DOCNO>NCT02227784</DOCNO>
	<brief_summary>The purpose ACCENTUATE study evaluate whether study drug know evacetrapib effective treat participant high cholesterol atherosclerotic cardiovascular disease ( ASCVD ) and/or diabetes .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Participants With High Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Must treat atorvastatin 40 mg/day least 30 day prior screen Have LDLC &gt; 70 mg/deciliter ( dL ) nonHDLC &gt; 100 mg/dL Have screen triglyceride ≤400 mg/dL ( ≤4.5 millimoles/Liter ) Individuals ASCVD and/or individual type 1 type 2 diabetes Have hemoglobin A1c ( HbA1c ) &gt; 9.5 % New York Heart Association ( NYHA ) class III IV congestive heart failure History either transient ischemic stroke ischemic stroke &lt; 30 day History acute coronary syndrome ( ACS ) &lt; 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>